{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
mmae
to a specific field?
Status:
Investigational
Source:
NCT02565758: Phase 1 Interventional Completed Advanced Solid Tumors
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03500380: Phase 2/Phase 3 Interventional Active, not recruiting Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02988817: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab envedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02365662: Phase 1 Interventional Terminated Head and Neck Squamous Cell Carcinoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02837991: Phase 1 Interventional Terminated Renal Cell Carcinoma (RCC)
(2016)
Source URL:
Class:
CONCEPT
Status:
Designated
Source:
FDA ORPHAN DRUG:814521
Source URL:
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
